- Home
- RNG vs HCM Comparison
RNG vs HCM Comparison
Compare RNG & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNG | HCM |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | RNG | HCM |
|---|---|---|
| Price | $30.45 | $13.73 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 14 | 1 |
| Target Price | ★ $31.23 | $13.75 |
| AVG Volume (30 Days) | ★ 1.3M | 26.6K |
| Earning Date | 11-03-2025 | 08-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.14 | ★ 0.53 |
| Revenue | ★ $2,485,621,000.00 | $602,197,000.00 |
| Revenue This Year | $5.73 | N/A |
| Revenue Next Year | $4.49 | $15.54 |
| P/E Ratio | $215.54 | ★ $5.05 |
| Revenue Growth | ★ 5.45 | N/A |
| 52 Week Low | $20.59 | $11.51 |
| 52 Week High | $42.19 | $19.50 |
Technical Indicators
Market Signals| Indicator | RNG | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 65.70 | 30.11 |
| Support Level | $28.72 | $14.11 |
| Resistance Level | $29.80 | $14.27 |
| Average True Range (ATR) | 0.86 | 0.25 |
| MACD | 0.33 | -0.02 |
| Stochastic Oscillator | 97.06 | 7.13 |
Price Performance
Historical ComparisonAbout RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.